Pharma BD Deal Intelligence

Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical Limited) / GSK plc

2026 · Licensing/Option · Complete

Sino Biopharmaceutical's subsidiary Chia Tai Tianqing Pharmaceutical Group secured exclusive rights to commercialise GSK's inhaled respiratory products Trelegy Ellipta (triple therapy) and Anoro Ellipta (dual therapy) in mainland China. CTTQ is responsible for importing, distributing and promoting the products, and will recognise the resulting sales revenue. Financial terms were not disclosed. The agreement broadens an existing GSK-Sino Biopharmaceutical collaboration beyond liver disease into respiratory, following a May 2026 agreement covering GSK's hepatitis B candidate in mainland China. Global 2025 sales were GBP 3.0 billion for Trelegy and GBP 542 million for Anoro.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals